IPN10200 + IPN10200 Placebo + Dysport
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Upper Facial Lines
Conditions
Moderate to Severe Upper Facial Lines
Trial Timeline
Apr 6, 2021 → Mar 5, 2027
NCT ID
NCT04821089About IPN10200 + IPN10200 Placebo + Dysport
IPN10200 + IPN10200 Placebo + Dysport is a phase 1/2 stage product being developed by Ipsen for Moderate to Severe Upper Facial Lines. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04821089. Target conditions include Moderate to Severe Upper Facial Lines.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04821089 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Moderate to Severe Upper Facial Lines